I'm hoping to see some more responses and good DOR from the RP2 trial.
Yes, in Q1 2022
• Initial single agent data in all comers in the RP3 PhI. • Initial data from RP1 plus Opdivo in anti-PD-1 failed CSCC. • RP1 single agent initial data in CSCC organ transplant patients. • Also, details on RP2/3 development strategy.
Then, Q4
• CERPASS (CSCC registration-directed trial) primary read out trigger. • IGNYTE (anti-PD-1 failed melanoma registration-directed trial) read out. • RP1 plus Opdivo in anti-PD1 failed NSCLC data. • RP1 plus Opdivo in anti-PD1 failed CSCC updated. • RP1 single agent data in CSCC organ transplant patients. • RP2 liver mets cohort expansion data. • Initial data from anti-PD-1 combination cohort with RP3.